Respiratory Syncytial Virus (RSV) Clinical Trials

A listing of Respiratory Syncytial Virus (RSV) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 63 clinical trials
A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age (RSVictory)

coadministered influenza vaccine on the immune response to RSV; and to evaluate the impact of coadministered RSV vaccine on the immune response to influenza.

Accepts healthy volunteers
  • 02 May, 2022
  • 1 location
A Study to Evaluate the Safety and Efficacy of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥60 Years of Age

episode of RSV-associated lower respiratory tract disease (RSV-LRTD) as compared with placebo from 14 days postinjection through 12 months.

Accepts healthy volunteers
  • 22 Mar, 2022
  • 22 locations
A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants

The purpose of the study is to evaluate the efficacy of study vaccine in the prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-confirmed RSV mediated- lower Respiratory

  • 26 Jul, 2022
  • 30 locations
Safety and Immunogenicity of RSVpreF Coadministered With SIIV in Adults ≥65 Years of Age

followed by RSVpreF). Additionally, the study will contribute data supporting the development of RSVpreF as a prophylactic vaccine against RSV disease in infants through maternal immunization and in older

Accepts healthy volunteers
  • 28 Jul, 2022
  • 32 locations
Safety and Immunogenicity of an Intranasal Vaccine for Respiratory Syncytial Virus in Seronegative Children 6-36 Months

This study evaluates an investigational vaccine that is designed to protect humans against infection with respiratory syncytial virus (RSV) and is administered as a nasal spray. Specifically

Accepts healthy volunteers
  • 10 Aug, 2022
  • 6 locations
Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults

, MV-014-212, is a live attenuated vaccine against respiratory syncytial virus (RSV) that is expressing the spike (S) protein of SARS-CoV-2. MV-014-212 is administered as drops or a spray in the nose

  • 18 Jul, 2021
  • 2 locations
Metabolism of Bioactive Dietary Polyphenol Preparation (BDPP)

juice (CGJ), a select grape seed polyphenol extract (GSPE) and trans-resveratrol (RSV).

  • 25 Jun, 2021
  • 1 location
Dynamic Change and Immune Response to Nasopharyngeal Carriage and Acute Otitis Media Pathogens

The investigators seek to conduct a prospective, longitudinal study to identify the dynamic changes in nasopharyngeal (NP) colonization patterns and acute otitis media (AOM) etiology involving antibiotic-resistant Streptococcus pneumoniae (Spn) and Haemophilus influenzae (Hflu).

  • 23 Jul, 2021
  • 1 location
MK-1654 in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)

This study aims to evaluate the safety and tolerability of MK-1654 compared to palivizumab as assessed by the proportion of participants experiencing adverse events (AEs).

  • 28 Jul, 2022
  • 60 locations
A Study of Various Respiratory Syncytial Virus (RSV) Pre-Fusion (preF)-Based Vaccine Formulations in Adults Aged 60 Years and Older

The purpose of the study is to evaluate safety and immunogenicity of various respiratory syncytial virus (RSV) pre-Fusion (preF)-based vaccine components followed by expanded safety evaluation

Accepts healthy volunteers
  • 11 Aug, 2022
  • 11 locations